Latest Insider Transactions at Encompass Health Corp (EHC)
This section provides a real-time view of insider transactions for Encompass Health Corp (EHC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Encompass Health Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Encompass Health Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 24
2024
|
Elissa Joy Charbonneau Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-34.97%
|
$850,000
$85.02 P/Share
|
|
May 06
2024
|
John Patrick Darby EVP, Gen Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
14,543
-14.64%
|
$1,207,069
$83.94 P/Share
|
|
May 06
2024
|
John Patrick Darby EVP, Gen Counsel & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
14,543
+12.77%
|
$421,747
$29.06 P/Share
|
|
May 03
2024
|
Greg D Carmichael Director |
BUY
Open market or private purchase
|
Direct |
2,000
+10.5%
|
$166,000
$83.73 P/Share
|
|
May 02
2024
|
Christopher R Reidy Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,978
+14.76%
|
-
|
|
May 02
2024
|
Nancy M Schlichting Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,978
+9.17%
|
-
|
|
May 02
2024
|
Terrance Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,978
+12.72%
|
-
|
|
May 02
2024
|
Leslye G Katz Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,978
+4.13%
|
-
|
|
May 02
2024
|
Patricia Anne Maryland Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,978
+13.01%
|
-
|
|
May 02
2024
|
Kevin J. O'Connor Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,978
+19.08%
|
-
|
|
May 02
2024
|
Greg D Carmichael Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,978
+11.62%
|
-
|
|
May 02
2024
|
Edward M Christie Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,978
+34.34%
|
-
|
|
May 02
2024
|
Joan E Herman Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,978
+4.13%
|
-
|
|
Apr 30
2024
|
Mark J Tarr President & CEO |
SELL
Open market or private sale
|
Direct |
44,976
-7.51%
|
$3,733,008
$83.27 P/Share
|
|
Apr 30
2024
|
Mark J Tarr President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
44,976
+3.68%
|
$1,439,232
$32.45 P/Share
|
|
Apr 16
2024
|
Edward M Christie Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
314
+14.83%
|
$24,806
$79.65 P/Share
|
|
Apr 16
2024
|
Christopher R Reidy Director |
BUY
Grant, award, or other acquisition
|
Direct |
411
+4.17%
|
$32,469
$79.56 P/Share
|
|
Apr 16
2024
|
John Chidsey Director |
BUY
Grant, award, or other acquisition
|
Direct |
234
+0.14%
|
$18,486
$79.52 P/Share
|
|
Apr 15
2024
|
Edward M Christie Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
2
+0.13%
|
-
|
|
Apr 15
2024
|
Nancy M Schlichting Director |
BUY
Grant, award, or other acquisition
|
Direct |
33
+0.19%
|
-
|
|
Apr 15
2024
|
Terrance Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
21
+0.18%
|
-
|
|
Apr 15
2024
|
Patricia Anne Maryland Director |
BUY
Grant, award, or other acquisition
|
Direct |
21
+0.19%
|
-
|
|
Apr 15
2024
|
Kevin J. O'Connor Director |
BUY
Grant, award, or other acquisition
|
Direct |
11
+0.17%
|
-
|
|
Apr 15
2024
|
Christopher R Reidy Director |
BUY
Grant, award, or other acquisition
|
Direct |
13
+0.14%
|
-
|
|
Apr 15
2024
|
Leslye G Katz Director |
BUY
Grant, award, or other acquisition
|
Direct |
80
+0.18%
|
-
|
|
Apr 15
2024
|
Joan E Herman Director |
BUY
Grant, award, or other acquisition
|
Direct |
80
+0.18%
|
-
|
|
Apr 15
2024
|
Donald L Correll Director |
BUY
Grant, award, or other acquisition
|
Direct |
184
+0.18%
|
-
|
|
Apr 15
2024
|
John Chidsey Director |
BUY
Grant, award, or other acquisition
|
Direct |
176
+0.11%
|
-
|
|
Apr 15
2024
|
Greg D Carmichael Director |
BUY
Grant, award, or other acquisition
|
Direct |
21
+0.16%
|
-
|
|
Feb 28
2024
|
John Patrick Darby EVP, Gen Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
15,928
+8.5%
|
-
|
|
Feb 28
2024
|
Edmund Fay Sr. Vice Pres. and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+3.29%
|
-
|
|
Feb 28
2024
|
Andrew L Price Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,398
+4.65%
|
-
|
|
Feb 28
2024
|
Mark J Tarr President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
89,500
+7.38%
|
-
|
|
Feb 28
2024
|
Elissa Joy Charbonneau Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,090
+14.1%
|
-
|
|
Feb 28
2024
|
Douglas E Coltharp EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,068
+10.61%
|
-
|
|
Feb 25
2024
|
Mark J Tarr President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,895
-0.62%
|
$217,125
$75.25 P/Share
|
|
Feb 25
2024
|
Douglas E Coltharp EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,079
-1.04%
|
$80,925
$75.25 P/Share
|
|
Feb 25
2024
|
Elissa Joy Charbonneau Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
506
-2.53%
|
$37,950
$75.25 P/Share
|
|
Feb 25
2024
|
Edmund Fay Sr. Vice Pres. and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
384
-0.4%
|
$28,800
$75.25 P/Share
|
|
Feb 25
2024
|
John Patrick Darby EVP, Gen Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
509
-0.73%
|
$38,175
$75.25 P/Share
|
|
Feb 25
2024
|
Andrew L Price Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
410
-0.59%
|
$30,750
$75.25 P/Share
|
|
Feb 24
2024
|
Mark J Tarr President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,256
-0.48%
|
$169,200
$75.25 P/Share
|
|
Feb 24
2024
|
Douglas E Coltharp EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
840
-0.8%
|
$63,000
$75.25 P/Share
|
|
Feb 24
2024
|
Elissa Joy Charbonneau Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
356
-1.75%
|
$26,700
$75.25 P/Share
|
|
Feb 24
2024
|
Edmund Fay Sr. Vice Pres. and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
299
-0.31%
|
$22,425
$75.25 P/Share
|
|
Feb 24
2024
|
John Patrick Darby EVP, Gen Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
397
-0.57%
|
$29,775
$75.25 P/Share
|
|
Feb 24
2024
|
Andrew L Price Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
320
-0.46%
|
$24,000
$75.25 P/Share
|
|
Feb 23
2024
|
Mark J Tarr President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,487
-0.53%
|
$186,525
$75.25 P/Share
|
|
Feb 23
2024
|
Douglas E Coltharp EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
927
-0.87%
|
$69,525
$75.25 P/Share
|
|
Feb 23
2024
|
Elissa Joy Charbonneau Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
434
-2.09%
|
$32,550
$75.25 P/Share
|